The C-reactive Protein to Albumin Ratio has been demonstrated to predict unfavorable outcomes in colorectal cancer, oral squamous cell carcinoma, gallbladder cancer, lung cancer, and thoracic esophageal cancer (33–37). This evidence concerns the gene ALB and lung carcinoma.